Navigation Links
Alzheimer Disease - New Drugs, Markets and Companies - 2013
Date:3/19/2013

DUBLIN, March 19, 2013 /PRNewswire/ --

Research and Markets has announced the addition of Jain PharmaBiotech's new market research report "Alzheimer Disease - New Drugs, Markets and Companies - 2013" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.

Early diagnosis of Alzheimer's disease is an important first step in management. Several biomarkers in cerebrospinal fluid, blood and urine can detect the disease. They provide a valuable aid to the clinical examination and neuropsychological testing which are the main diagnostic methods supplemented by brain imaging. Genotyping, particularly of ApoE gene alleles is also useful in the evaluation of cases and planning management.

The current management of Alzheimer's disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer's disease is being recognized.

Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Selected 185 clinical trials are listed, of which 131 are still in progress and 54 were discontinued for various reasons.

Alzheimer's disease market in the seven major markets is analyzed for the year 2012. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2022. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

Profiles of 144 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 97 collaborations. The bibliography contains over 850 publications that are cited in the report.The report is supplemented with 45 tables and 15 figures.

Key Topics Covered:

Executive Summary

1. Clinical Features, Epidemiology and Pathology

2. Diagnostic Procedures for Alzheimer Disease

3. Management of Alzheimer Disease

4. Research in Alzheimer Disease

5. Drug Discovery & Development for Alzheimer Disease

6. Markets & Finances of AD Care

7. Companies

8. References

For more information visit Alzheimer Disease - New Drugs, Markets and Companies - 2013

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends."

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Modeling Alzheimers disease using iPSCs
2. Is There a Natural Cure for Alzheimer's and Other Dementias?
3. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space
4. Leuven research opens new pathway for the treatment of Alzheimers disease
5. World Alzheimers Day - 21 September 2012
6. Alzheimers Therapeutics Reviewed by NeuroPerspective
7. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
8. First detailed timeline established for brains descent into Alzheimers
9. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
10. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline
11. Scientists gain new understanding of Alzheimers trigger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, ... could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma ... read it now. , Biomarkers are components in the blood, tissue or ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):